Search

Your search keyword '"Braunwald, Eugene"' showing total 94 results

Search Constraints

Start Over You searched for: Author "Braunwald, Eugene" Remove constraint Author: "Braunwald, Eugene" Database OpenAIRE Remove constraint Database: OpenAIRE
94 results on '"Braunwald, Eugene"'

Search Results

1. Transmethylamine-N-Oxide Is Associated With Diffuse Cardiac Fibrosis in People Living With HIV

2. Valsartan in early-stage hypertrophic cardiomyopathy:a randomized phase 2 trial

3. Sacubitril/Valsartan in Advanced Heart Failure with Reduced Ejection Fraction: Rationale/Design of the LIFE Trial

4. Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS-TIMI 54

5. Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: Insights from ENGAGE AF-TIMI 48

6. Sharing Data from Cardiovascular Clinical Trials — A Proposal

7. Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction

8. Valsartan for attenuating disease evolution in early sarcomeric hypertrophic cardiomyopathy: the design of the valsartan for attenuating disease evolution in early sarcomeric hypertrophic cardiomyopathy (vanish) trial

9. Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

10. Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48

11. Ezetimibe added to statin therapy after acute coronary syndromes

13. Rationale and Design of the Aldosterone Targeted NeuroHormonal CombinEd with Natriuresis TherApy in Heart Failure (ATHENA-HF) Trial

14. Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48)

15. Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48)

16. Causes of late mortality with dual antiplatelet therapy after coronary stents

17. Abstract 19694: Reduction in Non-hemorrhagic Stroke With Ezetimibe/Simvastatin Compared With Simvastatin Alone in the IMPROVE-IT Trial

18. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials

19. Enoxaparin versus Unfractionated Heparin with Fibrinolysis for ST-Elevation Myocardial Infarction

20. New ischemic stroke and outcomes with vorapaxar versus placebo: results from the TRA 2 °P-TIMI 50 trial

21. Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure)

22. Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48

23. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials

24. Outcome and Profile of Women and Men Presenting With Acute Coronary Syndromes: A Report From TIMI IIIB fn1fn1The TIMI IIIB Clinical Centers were supported by Grant R01-HL42311, the Central Units by Grant R01-HL42419 and the Data Coordinating Center by Grant R01-HL42428 from the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland

25. Rivaroxaban in patients with a recent acute coronary syndrome

27. Early Dynamic Risk Stratification with Baseline Troponin Levels and 90-minute ST Segment Resolution to Predict 30 Day Cardiovascular Mortality in STEMI: Analysis from CLARITY TIMI-28

28. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies

29. National Heart, Lung, and Blood Institute working group on emergency department management of acute heart failure: research challenges and opportunities

30. Meeting report ESC forum on drug eluting stents, European Heart House, Nice, 27-28 September 2007

31. Meeting Report

32. ESC Forum on Drug Eluting Stents European Heart House, Nice, 27-28 September 2007

33. State of the art: Using natriuretic peptide levels in clinical practice

35. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation

36. Reply

37. Reply

38. Reply

39. Reply

40. Association Between Angiographic Complications and Clinical Outcomes Among Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention An EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non–ST-Segment Elevation Acute Coronary Syndrome) Angiographic Substudy

41. Ischemia Detected on Continuous Electrocardiography After Acute Coronary Syndrome Observations From the MERLIN–TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non–ST-Elevation Acute Coronary Syndrome–Thrombolysis In Myocardial Infarction 36) Trial

42. An Invasive or Conservative Strategy in Patients With Diabetes Mellitus and Non–ST-Segment Elevation Acute Coronary Syndromes A Collaborative Meta-Analysis of Randomized Trials

43. Discharge Aspirin Dose and Clinical Outcomes in Patients With Acute Coronary Syndromes Treated With Prasugrel Versus Clopidogrel An Analysis From the TRITON–TIMI 38 Study (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis In Myocardial Infarction 38)

44. Rivaroxaban in Patients Stabilized After a ST-Segment Elevation Myocardial Infarction Results From the ATLAS ACS-2–TIMI-51 Trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome–Thrombolysis In Myocardial Infarction-51)

45. Prasugrel Versus Clopidogrel in Patients With ST-Segment Elevation Myocardial Infarction According to Timing of Percutaneous Coronary Intervention A TRITON–TIMI 38 Subgroup Analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel–Thrombolysis In Myocardial Infarction 38)

46. Prognostic implications of elevated troponin in patients with suspected acute coronary syndrome but no critical epicardial coronary disease A TACTICS-TIMI-18 substudy

47. B-Type Natriuretic Peptide and the Effect of Ranolazine in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes Observations From the MERLIN–TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary–Thrombolysis In Myocardial Infarction 36) Trial

48. Predictors of late development of heart failure in stable survivors of myocardial infarction The CARE study

49. Serial Measurement of Monocyte Chemoattractant Protein-1 After Acute Coronary Syndromes Results From the A to Z Trial

50. Application of the Thrombolysis In Myocardial Infarction Risk Index in Non–ST-Segment Elevation Myocardial Infarction Evaluation of Patients in the National Registry of Myocardial Infarction

Catalog

Books, media, physical & digital resources